OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (“Nordic Nanovector” or “the Company”) today announced that data from Betalutin’s Phase I/II trial will be presented in a poster session at the American Society of Hematology (ASH) 2014 Annual Meeting (December 6-9) in San Francisco. The poster reports the preliminary efficacy and safety data of patients with relapsed NHL enrolled in a 3+3 dose escalation Phase I study testing 3 different dose levels of Betalutin™. “We are looking forward to presenting the clinical results for Betalutin, the first radioimmunotherapeutic solution targeting CD-37 receptors on lymphoma cells that, thanks to its unique multi-cell kill approach, can deliver a robust clinical activity with a predictable safety profile,“ said Nordic Nanovector CEO, Luigi Costa.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
